XML 102 R88.htm IDEA: XBRL DOCUMENT v3.19.1
Related Party Transactions - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2017
Mar. 31, 2017
Jun. 30, 2016
Nov. 30, 2015
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Related Party Transaction [Line Items]              
Related party payables         $ 2,173,000   $ 256,000
Shares issued as payment for services         831,000 $ 2,941,000  
Noncash dividend income         12,000 4,883,000  
Fair value of financial assets measured at fair value on a recurring basis         77,283,000   122,181,000
Revenues         23,335,000 39,666,000  
Third Security, LLC              
Related Party Transaction [Line Items]              
Initial term of services agreement       1 year      
Expense for services         17,000 14,000  
Shares issued as payment for services           $ 2,041,000  
Shares issued as payment for services (in shares)           160,626  
Sublease rental income         22,000 $ 21,000  
Third Security, LLC | Common Stock              
Related Party Transaction [Line Items]              
Expense for services       $ 800,000      
Related party payables         2,078,000    
Convertible Note and Warrants | Other Noncurrent Assets | Fibrocell Science, Inc.              
Related Party Transaction [Line Items]              
Fair value of financial assets measured at fair value on a recurring basis         $ 156,000   120,000
Fibrocell Science, Inc.              
Related Party Transaction [Line Items]              
Convertible preferred shares issued (in shares)   1,161          
Warrants, number of common shares into which warrants can be converted (in shares)   99,769          
Convertible preferred shares, dividend rate   4.00%          
ZIOPHARM Oncology, Inc.              
Related Party Transaction [Line Items]              
Preferred shares, stated value (in usd per share)     $ 1,200        
Preferred shares, dividend rate (in usd per share)     $ 12.00        
Third Security, LLC | Chief Executive Officer              
Related Party Transaction [Line Items]              
Ownership interest         100.00%    
Collaboration and licensing agreements              
Related Party Transaction [Line Items]              
Revenues         $ 5,970,000 19,848,000  
Collaboration and licensing agreements | Histogenics Corporation, OvaScience Inc., and Synthetic Biologics Inc.              
Related Party Transaction [Line Items]              
Revenues           $ 3,183,000 11,877,000
ZIOPHARM Oncology, Inc.              
Related Party Transaction [Line Items]              
Dividend income, number of preferred shares received (in shares)           3,624  
Noncash dividend income           $ 4,871,000  
Fibrocell Science, Inc.              
Related Party Transaction [Line Items]              
Purchases of preferred stock and warrants   $ 1,161,000          
Preferred stock | Fibrocell Science, Inc. | Other Noncurrent Assets              
Related Party Transaction [Line Items]              
Fair value of financial assets measured at fair value on a recurring basis         248,000   191,000
Preferred stock | Oragenics, Inc.              
Related Party Transaction [Line Items]              
Fair value of financial assets measured at fair value on a recurring basis         $ 0   $ 0
Receivables converted to preferred stock $ 3,385,000            
Preferred shares, initial dividend rate         12.00%    
Preferred shares, subsequent dividend rate         20.00%    
ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements              
Related Party Transaction [Line Items]              
Collaborative arrangement consideration received, number of preferred shares (in shares)     100,000        
Revenues         $ 1,166,000 $ 5,377,000